as well as a €1 million loan from Bpifrance
PARIS, July 19, 2021 /PRNewswire/
PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announced today that it raised an additional €2.6 million ($3 million) in an extension of its Series A financing round, bringing the total raised in this round to €5.4 million ($6.4 million). This new funding comprises €1.6 million in equity from Anaxago, i&i Prague and BADGE as well as a €1 million loan from Bpifrance.
This increased financial support highlights the potential of PEP-010, as well as PEP-Therapy s Cell Penetrating & Interfering Peptide (CP&IP) technology platform, which was first developed at Sorbonne University and Institut Curie.
PEP-Therapy extends Series-A financing, raising a total of €5 4 million to progress the clinical development of its lead candidate PEP-010 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.